361 related articles for article (PubMed ID: 15927084)
21. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes.
Kanai R; Kar K; Anthony K; Gould LH; Ledizet M; Fikrig E; Marasco WA; Koski RA; Modis Y
J Virol; 2006 Nov; 80(22):11000-8. PubMed ID: 16943291
[TBL] [Abstract][Full Text] [Related]
22. Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity.
Boonyasuppayakorn S; Reichert ED; Manzano M; Nagarajan K; Padmanabhan R
Antiviral Res; 2014 Jun; 106():125-34. PubMed ID: 24680954
[TBL] [Abstract][Full Text] [Related]
23. PD1 CD44 antiviral peptide as an inhibitor of the protein-protein interaction in dengue virus invasion.
Recalde-Reyes DP; Rodríguez-Salazar CA; Castaño-Osorio JC; Giraldo MI
Peptides; 2022 Jul; 153():170797. PubMed ID: 35378215
[TBL] [Abstract][Full Text] [Related]
24. Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus.
Parkinson T; Pryde DC
Future Med Chem; 2010 Jul; 2(7):1181-203. PubMed ID: 21426163
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel target sites and an inhibitor of the dengue virus E protein.
Yennamalli R; Subbarao N; Kampmann T; McGeary RP; Young PR; Kobe B
J Comput Aided Mol Des; 2009 Jun; 23(6):333-41. PubMed ID: 19241120
[TBL] [Abstract][Full Text] [Related]
26. 5'-Silylated 3'-1,2,3-triazolyl Thymidine Analogues as Inhibitors of West Nile Virus and Dengue Virus.
Vernekar SK; Qiu L; Zhang J; Kankanala J; Li H; Geraghty RJ; Wang Z
J Med Chem; 2015 May; 58(9):4016-28. PubMed ID: 25909386
[TBL] [Abstract][Full Text] [Related]
27. Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus.
Anasir MI; Ramanathan B; Poh CL
Viruses; 2020 Mar; 12(4):. PubMed ID: 32225021
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Nanomolar Dengue and West Nile Virus Protease Inhibitors Containing a 4-Benzyloxyphenylglycine Residue.
Behnam MA; Graf D; Bartenschlager R; Zlotos DP; Klein CD
J Med Chem; 2015 Dec; 58(23):9354-70. PubMed ID: 26562070
[TBL] [Abstract][Full Text] [Related]
29. Peptide inhibition of human cytomegalovirus infection.
Melnik LI; Garry RF; Morris CA
Virol J; 2011 Feb; 8():76. PubMed ID: 21342525
[TBL] [Abstract][Full Text] [Related]
30. Peptide inhibitors of tembusu virus infection derived from the envelope protein.
Zhao D; Zhang L; Han K; Liu Q; Yang J; Huang X; Liu Y; Li Y; Zhao P
Vet Microbiol; 2020 Jun; 245():108708. PubMed ID: 32456819
[TBL] [Abstract][Full Text] [Related]
31. Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication.
Abdul Ahmad SA; Palanisamy UD; Tejo BA; Chew MF; Tham HW; Syed Hassan S
Virol J; 2017 Nov; 14(1):229. PubMed ID: 29162124
[TBL] [Abstract][Full Text] [Related]
32. A glycosylated peptide in the West Nile virus envelope protein is immunogenic during equine infection.
Hobson-Peters J; Toye P; Sánchez MD; Bossart KN; Wang LF; Clark DC; Cheah WY; Hall RA
J Gen Virol; 2008 Dec; 89(Pt 12):3063-3072. PubMed ID: 19008394
[TBL] [Abstract][Full Text] [Related]
33. Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope.
Lamb D; Schüttelkopf AW; van Aalten DM; Brighty DW
Retrovirology; 2008 Aug; 5():70. PubMed ID: 18680566
[TBL] [Abstract][Full Text] [Related]
34. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo.
Whitby K; Pierson TC; Geiss B; Lane K; Engle M; Zhou Y; Doms RW; Diamond MS
J Virol; 2005 Jul; 79(14):8698-706. PubMed ID: 15994763
[TBL] [Abstract][Full Text] [Related]
35. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease.
Nall TA; Chappell KJ; Stoermer MJ; Fang NX; Tyndall JD; Young PR; Fairlie DP
J Biol Chem; 2004 Nov; 279(47):48535-42. PubMed ID: 15322074
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein.
de Wispelaere M; Lian W; Potisopon S; Li PC; Jang J; Ficarro SB; Clark MJ; Zhu X; Kaplan JB; Pitts JD; Wales TE; Wang J; Engen JR; Marto JA; Gray NS; Yang PL
Cell Chem Biol; 2018 Aug; 25(8):1006-1016.e8. PubMed ID: 29937406
[TBL] [Abstract][Full Text] [Related]
37. How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion.
Chao LH; Jang J; Johnson A; Nguyen A; Gray NS; Yang PL; Harrison SC
Elife; 2018 Jul; 7():. PubMed ID: 29999491
[TBL] [Abstract][Full Text] [Related]
38. High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.
Balasubramanian A; Manzano M; Teramoto T; Pilankatta R; Padmanabhan R
Antiviral Res; 2016 Oct; 134():6-16. PubMed ID: 27539384
[TBL] [Abstract][Full Text] [Related]
39. Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with β3 integrin.
Cui X; Wu Y; Fan D; Gao N; Ming Y; Wang P; An J
Antiviral Res; 2018 Jul; 155():20-27. PubMed ID: 29709564
[TBL] [Abstract][Full Text] [Related]
40. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
Chu JH; Chiang CC; Ng ML
J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
